Skip to content

Reading an HPLC and NMR Report: What a Peak Can and Can’t Tell You

The science 4 min read P3 Project-authored synthesis

Chromatography and NMR reveal different aspects of a sample; learning their axes and signals helps readers understand the limits of each report.

By Eloralintide Research

A tall transparent laboratory column contains separate bands of vivid color beside blurred glass bottles and equipment.

Start With the Question, Not the Instrument

Analytical reports can look decisive. A chromatogram displays peaks. An NMR spectrum shows resonances. Labels and tables may make the whole page look like a final answer. But each method responds to a different physical property, and interpretation depends on a defined analytical question.

A useful reader first asks what the method was intended to identify or quantify, what sample was tested and how the method’s suitability was demonstrated. The ICH Q2(R2) guideline treats identification tests, assay and impurity tests as different analytical purposes with different validation expectations. [1] The FDA published Q2(R2) and the companion Q14 guideline on analytical procedure development as final guidance in March 2024. [2][3]

Reading the Axes of an HPLC Chromatogram

High-performance liquid chromatography separates components through interactions with mobile and stationary phases. A conventional chromatogram plots a detector response against time.

Retention time is the time at which a component’s detected signal appears under the specified method. It can help compare an unknown with a reference under controlled conditions. It is not, by itself, an unambiguous molecular identity.

Peak area reflects the integrated detector response for a chromatographic peak. Area depends on the measurement system, response factors and integration settings. The largest peak need not represent the claimed compound unless identity has been addressed separately.

What Area Percent Really Means

Area percent generally describes one peak’s area relative to a chosen total of integrated peak areas in the chromatogram. It does not automatically mean that the sample contains that percentage by mass of the target substance.

Differences in detector response, coelution, unobserved substances and method selectivity can influence the interpretation. The validity of a quantitative conclusion depends on an appropriate procedure and calibration strategy. Developing a method and validating it are separate steps, covered by ICH Q14 and Q2(R2) respectively. [1][2]

What an NMR Spectrum Shows

Nuclear magnetic resonance reports resonances associated with nuclei in particular chemical environments. A chemical shift describes where a signal appears relative to a reference, often presented on a parts-per-million scale.

Signals can overlap. Solvent, temperature, field conditions and molecular dynamics can affect interpretation. The presence of a recognizable resonance is not automatically proof of a whole molecular structure.

Understanding Integration

For an appropriate quantitative NMR experiment, signal integration can relate to the number of contributing nuclei. But that inference depends on acquisition conditions, relaxation behavior, signal resolution and a suitable reference when absolute quantity is being evaluated.

A casual glance at peak heights is not the same as properly interpreting integrated signals. The ICH Q2(R2) guideline includes quantitative proton NMR, using an internal standard, among its worked examples for the assay of a drug substance, and it expects such a method to be validated for its intended purpose. [1]

Why Complementary Methods Matter

HPLC provides evidence about chromatographic behavior and detected components. NMR provides a different type of structural information. Neither should be treated as a magical all-purpose verification method.

When an analytical question cannot be addressed adequately by one procedure, a complementary method may help. ICH Q2(R2) discusses specificity, meaning the need to demonstrate that an analytical method can distinguish the analyte from relevant alternatives or interferences, including by comparison with an orthogonal procedure. [1]

The Limits of One Report

An analytical report addresses the tested sample, method and attributes measured. It does not automatically establish every quality characteristic of an entire batch or any clinical property. Report authenticity, sampling and validation are separate questions.

This explainer deliberately contains no example sample result, no invented peak, no lot identifier and no implied structure determination.

The Bottom Line

A peak is a signal that requires interpretation. A spectrum is evidence that must be assessed under an appropriate method. Reading the axes, integration and intended analytical purpose is a practical defense against overclaiming.

FAQ

Does retention time identify a compound on its own?

No. Retention-time agreement can support comparison under a defined method, but it may not distinguish every possible interferent.

Is HPLC main-peak area percent the same as purity by mass?

Not automatically. The detector response and included peak population matter.

What does a chemical shift mean in NMR?

It indicates a resonance position associated with a nuclear chemical environment relative to a reference.

Does NMR integration always give an absolute quantity?

No. Quantitative interpretation requires suitable experimental conditions and calibration or reference methods.

Further reading: How to read an HPLC and NMR report, Eloralintide testing and Understanding the testing debate

Editorial note

This article discusses investigational drug research for educational purposes. It does not provide medical advice, treatment recommendations, or instructions for obtaining or administering experimental compounds. Clinical findings should be interpreted within their original study populations and methodological limitations.

Sources

  1. International Council for Harmonisation. ICH Q2(R2) Guideline on validation of analytical procedures. Adopted at ICH Step 4 on November 1, 2023. Official guideline text as published by the European Medicines Agency (Step 5). www.ema.europa.eu
  2. U.S. Food and Drug Administration. Q14 Analytical Procedure Development. Final guidance, March 2024. Regulator guidance page. www.fda.gov
  3. U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures. Final guidance, March 2024. Regulator guidance page. www.fda.gov

P3 Project-authored synthesis An analysis written for this publication from the sources above, checked against them before approval.